R&D update

Including launch of two new tests to differentiate between COVID-19 and common winter viruses, and between COVID-19 variants Paris, France and Camberley, UK – 30 September 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an R&D update. http://novacyt.com/wp-content/uploads/2021/09/Novacyt-RD-update.pdf

Visit Page

Notice of AGM

Paris, France and Camberley, UK – 29 September 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that following the announcement earlier today the Company’s rescheduled Annual General Meeting (AGM) will be held on Monday, 18 October 2021 at 2pm CEST/1pm BST. http://novacyt.com/wp-content/uploads/2021/09/Notice-of-AGM.pdf

Visit Page

Notice of rescheduled AGM

Paris, France and Camberley, UK – 29 September 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it will reschedule its Annual General Meeting (AGM) due to be held today at 2pm CEST/1pm BST to a later date. As usual, and in accordance with French corporate law, the

Visit Page

Half year 2021 results

Solid underlying financial performance and well-positioned for continued growthParis, France and Camberley, UK – 27 September 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its unaudited results for the half year ended 30 June 2021. http://novacyt.com/wp-content/uploads/2021/09/Novacyt-H1-results-final-.pdf

Visit Page

Proposed accounting treatment of ongoing DHSC dispute in 2021 interim results

Paris, France and Camberley, UK – 16 September 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces the proposed accounting treatment of the ongoing DHSC dispute on its unaudited H1 2021 interim results for the six months ended 30 June 2021. The interim results are expected to be announced

Visit Page

AGM voting

Paris, France and Camberley, UK – 13 September 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, will be holding its annual general meeting (AGM) as a closed meeting at 2pm CEST/1pm BST on Wednesday, 29 September 2021. As usual, and in accordance with French corporate law, the AGM comprises

Visit Page

David Allmond announced as CEO following decision by Graham Mullis to retire

Paris, France and Camberley, UK – 29 July 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), a leading international specialist in clinical diagnostics, announces the appointment of David Allmond as CEO and a member of the Board of Directors effective from 18 October 2021. At that time Graham Mullis, having informed the Board that he

Visit Page

Director/PDMR Shareholding

Paris, France and Camberley, UK – 06 July 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on 05 July 2021, Guillermo Raimondo, Chief Commercial Officer of the Company, acquired 10,000 ordinary shares of €1/15 each in the Company at a price of

Visit Page

Expansion of PathFlow® COVID-19 lateral flow test portfolio

Paris, France and Camberley, UK – 29 June 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is to launch two PathFlow® COVID-19 antigen lateral flow tests (LFTs) to strengthen the Company’s COVID-19 portfolio and to pursue significant new market opportunities, especially in point-of-care (POC) settings. The Company will initially

Visit Page

Full year 2020 results and update on growth strategy

Transformational performance in 2020Continued strong demand for COVID-19 testing in 2021Strategy to deliver long-term growth through test, instrument, and geographic expansion in key areas, supplemented by M&A http://novacyt.com/wp-content/uploads/2021/06/Novacyt-full-year-2020-results-Final-ENGLISH.pdf

Visit Page